Studies have shown that myeloid cell-derived S100A9 can increase blood supply and promote angiogenesis by inducing IL6 and IL10 to create a survival niche for subsequent tumor progression in multiple myeloma (De Veirman et al., 2017). This evidence concerns the gene IL6 and neoplasm.